20 Sep 2017
LIBERUM: Shield Therapeutics* - No material changes to our in-market sales expectations, US P3 now due early 2018, IDA label filed early
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LIBERUM: Shield Therapeutics* - No material changes to our in-market sales expectations, US P3 now due early 2018, IDA label filed early
Shield Therapeutics Plc (STX:LON) | 2.0 0 0.0% | Mkt Cap: 15.8m
- Published:
20 Sep 2017 -
Author:
Roger Franklin | Graham Doyle -
Pages:
4